

Datasheet: HCA294

BATCH NUMBER 157016

Description:	HUMAN ANTI VEDOLIZUMAB
Specificity:	VEDOLIZUMAB
Other names:	Entyvio
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD30138_hlgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
---------------------	--

Preparation	Purified IgG prepared by affinity chromatography on Protein A
--------------------	---

Buffer Solution	Phosphate buffered saline
------------------------	---------------------------

Preservative Stabilisers	0.01% Thiomersal
---------------------------------	------------------

Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
---------------------------------------	----------------------------------

Immunogen	Vedolizumab
------------------	-------------

Specificity	Human Anti-Vedolizumab Antibody, clone AbD30138_hlgG1 is a paratope specific,
--------------------	--

inhibitory anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug vedolizumab. The antibody does not recognize free recombinant human $\alpha 4\beta 7$ integrin or vedolizumab in complex with $\alpha 4\beta 7$ integrin and can be used to measure free vedolizumab levels in serum from patients.

Clone AbD30138_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a reference standard in an anti-drug antibody (ADA) assay. A pair of anti-vedolizumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in full immunoglobulin format, is recommended as the detection antibody paired with clone AbD30136 ([HCA292](#)) in monovalent Fab format as the capture antibody.

Vedolizumab (Entyvio) is a humanized antibody (IgG1/kappa), derived from a murine antibody. It is used for the treatment of both moderate to severe ulcerative colitis and moderate to severe Crohn's disease, primarily in patients who have lost response to, or are intolerant to inhibitors of tumor necrosis factor alpha (TNF α), such as infliximab, adalimumab. The drug binds specifically to human $\alpha 4\beta 7$ integrin, a key mediator of gastrointestinal inflammation expressed on the surfaces of T and B lymphocytes. By selectively inhibiting the binding of $\alpha 4\beta 7$ integrin to the mucosal addressin cell adhesion molecule-1 (MAdCAM-1), vedolizumab prevents leukocyte binding to the endothelial surface and extravasation into affected tissue. Specifically inhibiting this pathway alleviates gastrointestinal inflammation without impairing systemic immune responses.

[View a summary of all anti-vedolizumab antibodies](#)

Affinity	The monovalent intrinsic affinity of AbD30138_hIgG1 was measured as $K_D=1.5$ nM by real time, label-free molecular interaction analysis on immobilized vedolizumab.
-----------------	--

ELISA	Clone AbD30138_hIgG1 can be used in a direct or indirect ELISA or as detection antibody for vedolizumab in a bridging ELISA together with (HCA292) as the capture reagent. Furthermore, it may be used as a calibrator for the set-up of an anti-drug antibody assay.
--------------	---

Protocol: [PK bridging ELISA to measure free drug](#) and [ADA bridging ELISA](#).

Storage	+4°C or at -20°C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
----------------	--

Guarantee	12 months from date of despatch
------------------	---------------------------------

Acknowledgements	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Entyvio is a trademark of Millennium Pharmaceuticals, Inc.
-------------------------	--

Health And Safety Information	Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA294
--------------------------------------	--

Licensed Use	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual

Related Products

Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HUMAN ANTI VEDOLIZUMAB \(HCA292\)](#)

[MOUSE ANTI HUMAN IgG \(Fc\) CH2 DOMAIN:HRP \(MCA647P\)](#)

North & South Tel: +1 800 265 7376

America Fax: +1 919 878 3751

Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: antibody_sales_de@bio-rad.com

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets

'M371734:200612'

Printed on 12 Sep 2024